<DOC>
	<DOCNO>NCT01735175</DOCNO>
	<brief_summary>The study assess efficacy LA-EP2006 compare Peg-Filgrastim respect mean duration severe neutropenia treatment myelosuppressive chemotherapy breast cancer patient .</brief_summary>
	<brief_title>Phase III Study Comparing Efficacy Safety LA-EP2006 NeulastaÂ®</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>histologically prove breast cancer eligible six cycle neoadjuvant adjuvant chemotherapy concurrent prior chemotherapy breast cancer concurrent prior anticancer treatment breast cancer endocrine therapy , immunotherapy , monoclonal antibody , and/or biological therapy concurrent prophylactic antibiotic previous therapy GCSF ( granulocytecolony stimulate factor ) product Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prevention neutropenic complication breast cancer patient</keyword>
	<keyword>Pegfilgrastim ,</keyword>
	<keyword>G-CSF ,</keyword>
	<keyword>neutropenia ,</keyword>
	<keyword>breast cancer ,</keyword>
	<keyword>myelosuppressive chemotherapy ,</keyword>
	<keyword>supportive care</keyword>
</DOC>